A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
19/11/2021at 13:00

Competitors turned collaborators: Dicerna acquisition sends Novo Nordisk into the arms of rivals Eli Lilly and Boehringer Ingelheim

Over the years, the US-based company Dicerna has partnered with several companies within several of Novo Nordisk's strategically important disease areas. With Wednesday's announcement, Novo Nordisk now finds itself in the peculiar position of being partnered with its competitors, including its arch-rival Eli Lilly.
Photo: NOVO NORDISK
BY ULRICH QUISTGAARD AND MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN

From now on, Novo Nordisk is no longer just a competitor of Boehringer Ingelheim and Eli Lilly – it is also a close collaborator.

Both companies have entered into research and development partnerships with the US-based Dicerna, which Novo Nordisk is now in the process of acquiring after having made a takeover bid of USD 3.3bn. The new partnership will center on disease areas of interest to Novo Nordisk, such as the non-alcoholic fatty liver disease known as NASH and cardiometabolic diseases.

Eli Lilly is currently Novo Nordisk's biggest competitor on the diabetes market and an upcoming challenger in the obesity area, whereas Boehringer Ingelheim has also moved into Novo Nordisk's fields of interest with the diabetes and heart failure drug Jardiance, which it markets alongside Eli Lilly, and its several drug candidates for NASH.

"We are obviously fully aware of the fact that the deal puts us in this situation, and we will absolutely honor and find mechanisms to work with these collaborations going forward," says Marcus Schindler, executive vice president and chief scientific officer at Novo Nordisk, to MedWatch.

However, he emphasizes that as of now, it is unknown what will happen with the other partnerships as Novo Nordisk cannot speak on behalf of the other parties involved.

"It's a two-way process, and first of all, the aim is for all parties to honor the existing contracts," Schindler says.

Early stage partnerships

Both Boehringer Ingelheim and Eli Lilly signed deals with Dicerna before Novo Nordisk entered the picture.

Eli Lilly's collaboration is the most advanced and has, for the time being, yielded two candidates making it to clinical development, where they are being tested in a phase I trial against unnamed cardiometabolic diseases.

An additional three preclinical drug candidates targeting the same therapy area have come from the partnership.

As for Boehringer Ingelheim, its collaboration with Dicerna, which was initiated in 2017, has been about new treatments for chronic liver diseases, including the fatty liver disease NASH. Novo Nordisk has been hoping to one day be able to treat the same disease, and the pharmaceutical company is currently testing the molecule semaglutide against it, just as NASH is one of the focus areas of Novo Nordisk's new deal with Dicerna.

Despite overlapping interests, says Schindler, Novo Nordisk has no intentions of terminating the partnerships with Boehringer Ingelheim, Eli Lilly, and others, and the parties are also contractually bound.

"They are our competitors just as we're their competitors. It is up to the other parties in this equation to see where they would like to take their existing collaborations with Dicerna," says Schindler.

Into the Novo Nordisk fold

Once the acquisition has concluded, Dicerna and its 300 employees will join the Novo Nordisk fold – they will, however, retain their base in Lexington, Massachusetts.

"We will maintain their biotech spirit as much as possible by turning it into a transformational research unit," says Schindler, underscoring that a number of Novo Nordisk's existing R&D units already function with a high degree of autonomy from the parent company.

"The way it works is that through strong leadership, ring-fenced budget decision making and the important part – they are distinct from a spinout, for example, as we are cognizant of synergies, open communication and strong collaboration with other parts within Novo Nordisk. So it's truly trying to both integrate, without assimilating, and to keep the biotech spirit to move fast, while also benefitting from the powerhouse that we have built internally within research and early development," Schindler explain.

Does that mean the company will get to keep the Dicerna name, or will it be called Novo Nordisk in the future?

"That is actually not a decision we have made at this point in time," the EVP says.

Partnership options have an unclear future

Another aspect that remains unclear at the moment is Dicerna's possibility of entering into new collaborations and partnerships in the future.

Schindler explains that Novo Nordisk will do its utmost to keep Dicerna's flexibility alive, adding that several of the parent company's R&D units have plenty of partnership options.

"Our translational transformation research unit for the cell therapy actually lives and breathes through collaborations, so we see collaborations as a way to enhance Dicerna's platform technology. But of course, it's a discussion that will need to be had at a later date about the definition and the scope of those partnerships, but we certainly don't want to lock Dicerna into being an immobile unit," says Schindler.

Novo Nordisk acquires Dicerna for USD 3.3bn

Huge acquisition scores Novo Nordisk an FDA-ready treatment

Eli Lilly reaps rewards of Novo acquisition

Semaglutide fails in phase II trial within fatty liver disease

New unit to bring Novo Nordisk closer to goal of using RNA and gene therapies across all treatment areas

Related articles:

  • Photo: POOL New/REUTERS / X80003

    Semaglutide fails in phase II trial within fatty liver disease

    For subscribers

  • Photo: Novo Nordisk / PR

    Eli Lilly reaps rewards of Novo acquisition

    For subscribers

  • Photo: Tidsvilde Stine/Ritzau Scanpix

    Novo Nordisk acquires Dicerna for USD 3.3bn

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Foto: Stine Bidstrup
Pharma & biotech

Potential blockbuster submitted by Novo Nordisk for European approval

The EMA can begin reviewing hemophilia treatment concizumab, which used to carry the orphan drug badge until recently, when the company decided not to take advantage of the status.
  • Novo Nordisk renounces orphan drug title for potential blockbuster
  • Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

For subscribers

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Further reading

Anders Hinsby (left), Thomas Kirkegaard Jensen, and Anders Vadsholt | Foto: Anne Bæk/Ritzau Scanpix
Pharma & biotech

Orphazyme trio founds new firm focused on neurology and rare diseases

Anders Hinsby, Anders Vadsholt, and Thomas Kirkegaard Jensen – all three key figures from now-defunct biotech company Orphazyme – have established a new company using experiences from the past.

For subscribers

Foto: Novo Nordisk / PR
Pharma & biotech

Novo Nordisk wins case in US appeals court

Three pharmaceutical firms, including Novo Nordisk, have won a case in a US appeals court, which agreed that the drugmakers can limit deliveries of federally discounted drugs.

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

For subscribers

Latest news

  • Potential blockbuster submitted by Novo Nordisk for European approval – 13:51
  • Novo Nordisk sues Viatris over copycat Wegovy – 12:46
  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
See all

Jobs

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of Regulatory Affairs Danmark

  • Application Manager

See all jobs

Jobs

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of Regulatory Affairs Danmark

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge